Bringing New Biotech Treatments to Market

How much do you need to be already thinking about how your interventions will fit into the broader healthcare system, specifically like insurance and hospitals and all the other downstream infrastructure? Definitely, yeah. Again, we try to make that easier by going first after diseases where that's already been mapped out. So we're not inventing the disease. It's not a new one. We know there's a clear payer strategy. This is really important from a regulatory risk. Will the FDA even accept these clinical trial endpoints? Are they meaningful and will the payers pay for it at the end of the day? So these are really critically important. Like that's an important part of de risking your program. I will say though. But right. Like we do have this longer term vision that these therapies are not just going to treat an acute disease, but they might be, you know, a drug for frailty or a drug for immune dysfunction, maybe used prophylactically. Like a great example today is something like a statin. It's prescribed as though it were an aging drug. Right. Like if you're over 40, you have a couple of risk biomarkers, your doctor will prescribe a statin. And they weren't first approved that way. They were first approved for familial hypercholesterolemia, like a narrow orphan disease. And the label was widened over time. So this is a path that's been trotted before in terms of start with a very narrow indication, broaden over time to a big one. And the question for us looking to the future is like, can we accelerate that? Right. Like what is. Like, we believe there are going to be these therapies that fundamentally move the needle on aging and how do we actually get them to the largest population that can benefit as rapidly as possible? So that's more. I would say that's a harder question. Right. But we are doing some work on that now to really realize the full value of these therapies and help the most patients.